ICCC

Business Context and Reporting Period

Company: ImmuCell Corporation (IMMUCELL CORP)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: ImmuCell is a biotechnology company focused on developing, manufacturing, and selling diagnostic tests and therapeutic products for the dairy and beef industries. Since 1999, the company has shifted its strategic focus from human health applications to animal health, resulting in six consecutive years of net income. Key products include First Defense (calf scours prevention), Wipe Out Dairy Wipes (mastitis management), and MASTiK (antibiotic susceptibility testing).

Key Financial Metrics (Year Ended Dec 31, 2004)

Note: The increase in long-term liabilities is primarily due to deferred revenue from a new licensing agreement.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by 10% ($339,000) compared to 2003. Product sales rose 12% ($379,000), driven primarily by a 17% increase in sales of First Defense. This growth correlates with a 35% increase in the Class III milk price index in 2004.
• Profitability Decline: Net income decreased significantly by 65% ($267,697) to $143,519. This decline is largely attributable to the absence of a $1,100,000 one-time gain in 2003 from the sale of the company's interest in a joint venture (AgriCell).
• Expense Management: R&D expenses decreased by 19% ($258,000) as the company completed a major field trial for Mast Out in 2003. Selling expenses decreased by 19% ($92,000), improving to 11% of product sales.
• Strategic Partnership: In December 2004, the company entered a product development and marketing agreement with Pfizer Animal Health for Mast Out, receiving a $1,500,000 upfront payment. Only $20,548 of this was recognized as revenue in 2004; the remainder is deferred.

Guidance, Outlook, and Risks

• Outlook: The company expects to continue focusing on animal health products. Pfizer is responsible for future clinical, regulatory, and commercial manufacturing development of Mast Out, with efficacy trials expected to begin in the first half of 2005. The company anticipates recognizing the deferred Pfizer revenue ratably through December 31, 2007.
• Regulatory Risks: Commercialization of Mast Out is contingent upon FDA approval, which cannot be assured. The company must demonstrate efficacy in pivotal studies and satisfy various "Technical Sections" including Human Food Safety.
• Market Risks: The company's primary customers (dairy producers) face economic pressures. While milk prices improved in 2004, historical volatility remains a risk. Additionally, the company relies heavily on the successful development of new products for future growth.
• Operational Risks: The company is dependent on its single manufacturing facility in Portland, Maine. Disruptions there could negatively impact production. There is also a risk regarding the stability of the "Reference Standard" for First Defense, which is required for USDA regulatory compliance.

Investor Verification Checklist

• Pfizer Agreement Terms: Verify the specific milestones and royalty rates in the December 2004 agreement with Pfizer, as future revenue is heavily dependent on these contingent payments.
• FDA Approval Timeline: Monitor the progress of the Mast Out pivotal efficacy trials scheduled for 2005 and the subsequent FDA New Animal Drug Application (NADA) review process.
• Deferred Revenue Recognition: Confirm the amortization schedule for the $1,500,000 Pfizer upfront payment and the $965,000 capitalized payment to Nutrition 21, Inc., as these impact future earnings.
• Customer Concentration: Review the dependency on the U.S. dairy industry and the impact of milk price fluctuations on sales volume for First Defense and Wipe Out.
• Regulatory Compliance: Assess the status of the USDA "Reference Standard" for First Defense to ensure no interruption in sales due to regulatory requalification requirements.